Why the study?
Cardiovascular disease remains the leading cause of death, exacerbated by diabetes and obesity, while novel antidiabetic agents show potential to improve glycemic control and reduce cardiovascular and renal morbidity.
SGLT2 inhibitors and GLP-1 receptor agonists provide significant cardio-renal benefits beyond glycemic control, shifting the paradigm towards integrated multi-system disease management.
Cardiovascular disease remains the leading global cause of death, with its burden exacerbated by rising rates of diabetes mellitus and obesity. Recent therapeutic advances have revealed the dual potential of novel antidiabetic agents—not only to improve glycemic control but also to significantly reduce cardiovascular and renal morbidity. This report explores the emerging roles of sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in cardiovascular disease management. Evidence from major clinical trials highlights their efficacy in reducing heart failure hospitalizations, atherosclerotic events, and in slowing the progression of chronic kidney disease. The discussion emphasizes the mechanisms beyond glycemic control that underpin their cardio-renal benefits, and reflects on the paradigm shift towards integrated, multi-system disease management. These developments signify a promising future where metabolic therapies play a central role in cardiovascular care.
No takes yet. Share an insight, caveat, or question.
Akshat Sinha (2025) conducted a review in Cardiovascular disease and diabetes mellitus. Sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: